课题基金 / 基金详情

Advancing Whole-Organism Screening for Chemical Modifiers of the Brain

Advancing Whole-Organism Screening for Chemical Modifiers of the Brain
推进大脑化学修饰物的整体有机体筛选
批准号:
8606524
负责人:
Adam R. Abate
金额:
$19.22万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-01 至 2016-01-31

项目摘要

项目成果

Adam R. Abate的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The suitability for large-scale screening and the transparent nature during embryonic and larval stages make zebrafish an attractive system for small molecule screening in an intact organism, with aims both to identify therapeutic compounds and to understand biological mechanisms. DA neurons degenerate in human Parkinson's disease (PD), a devastating neurodegenerative disorder for which there is currently no cure. Zebrafish, as a prominent vertebrate model organism with the ability to produce a large number of transparent embryos and larvae, is ideally suited for discovering small molecules that can regulate the development, maintenance, or regeneration of DA neurons. However, key limitations with whole organism-based chemical screening is low throughput and low resolution. In this proposal, we will advance whole organism screening by developing and integrating fast speed high-resolution whole-organism imaging with an improved microfluidics- based technology, using the DA neuron assay that we have already established. If successful, this platform will revolutionize the whole-organism screening capability and lead to novel small molecule compounds that can modify CNS development and function and provide leads for potential treatment of PD.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Next Generation Infectious Disease Diagnostics: Microfluidic-Free Gigapixel PCR with Self-Assembled Partitioning
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users
  • 批准号:
    10789790
  • 项目类别:
  • 资助金额:
    $163.09万
  • 财政年份:
    2023
  • 负责人:
    Adam R. Abate
  • 依托单位:
A non-invasive metabolic sensor for improving success in IVF
Identification of regulatory mechanisms operating in rare pathogenic astrocyte subsets in multiple sclerosis with a novel genomic technology
海外基金